10 recruiting, 7 not yet recruiting, 1 terminated. 18 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Recruiting 10, Not yet recruiting 7, Terminated 1 |
| Phase 1 | 5 | Not yet recruiting 2, Recruiting 2, Terminated 1 |
Follow Diffuse Large B Cell Lymphoma (DLBCL): new trials by email Literature Review of Diffuse Large B Cell Lymphoma (DLBCL) trials Research Report on Diffuse Large B Cell Lymphoma (DLBCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-11-01 | 2026-11-10 |
| A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas CART Infusion - Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma | Phase 2 | Not yet recruiting | Kure Cells, INC | 105 | 2026-08-31 | 2026-07-20 |
| A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Obinutuzumab, Glofitamab, Gemcitabine - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 96 | 2026-07-22 | 2026-07-13 |
| Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Medical College of Wisconsin | 31 | 2026-06-01 | 2026-08-25 |
| Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor - Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2026-04-01 | 2026-04-15 |
| Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study R-CHOP, POLA-R-CHP, Lisaftoclax - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 122 | 2026-02-28 | 2026-02-10 |
| Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma Zanubrutinib+Pola-R-CHP - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Beijing Tongren Hospital | 50 | 2025-11-20 | 2026-01-28 |
| Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma Anbal-cel - Primary CNS Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Hyungwoo Cho | 12 | 2025-11-12 | 2025-12-17 |
| A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma HDM2005, Rituximab or Rituximab biosimilar, Gemcitabine - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 97 | 2025-07-30 | 2025-08-15 |
| Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation Early start post-transplant vaccination with Gardasil 9®, Late post-transplant vaccination with Gardasil 9® - Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated | Phase 2 | Recruiting | Vastra Gotaland Region | 100 | 2025-05-12 | 2025-06-05 |
| Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) glofitamab - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | University Health Network, Toronto | 40 | 2025-01-24 | 2026-04-24 |
| A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma Glofitamab, Polatuzumab, Rituximab - Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 42 | 2025-01-16 | 2026-10-30 |
| Dynamic CtDNA-guided Targeted Therapy in DLBCL R-CHOP + X - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 108 | 2024-12-31 | 2024-12-27 |
| Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） Orelabrutinib Oral Tablet, R-CHOP Protocol - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Sun Yat-sen University | 39 | 2024-11-01 | 2024-10-22 |
| Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement R-CHOP+Z+MTX, R-CHOP+MTX - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 40 | 2024-10-01 | 2024-09-19 |
| GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies GEN3014, Daratumumab - Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | Genmab | 130 | 2021-03-09 | 2026-05-19 |
Lymphoma, Large B-Cell, Diffuse (18) · Leukemia, Myeloid, Acute (3) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Papillomavirus Infections (1) · Recurrence (1)
Hemic and Lymphatic Diseases (18) · Immune System Diseases (18) · Immunoproliferative Disorders (18) · Lymphatic Diseases (18) · Lymphoproliferative Disorders (18) · Neoplasms (18) · Neoplasms by Histologic Type (18) · Lymphoma, B-Cell (17) · Lymphoma (16) · Lymphoma, Non-Hodgkin (16) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, Myeloid (3) · Disease Attributes (2) · Pathologic Processes (2)
Cyclophosphamide (3) · Doxorubicin (3) · glofitamab (3) · Gemcitabine (2) · Oxaliplatin (2) · Prednisone (2) · R-CHOP protocol (2) · Rituximab (2) · obinutuzumab (2) · polatuzumab vedotin (2) · Filgrastim (1) · Human Papillomavirus Recombinant Vaccine nonavalent (1) · Lisaftoclax (1) · Sirolimus (1) · daratumumab (1)
Beijing Tongren Hospital (2) · Sun Yat-sen University (2) · AbelZeta Inc. (1) · Genmab (1) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1) · Hyungwoo Cho (1) · Kure Cells, INC (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1) · Ruijin Hospital (1) · The First Affiliated Hospital of Soochow University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Umoja Biopharma (1) · University Health Network, Toronto (1) · Vastra Gotaland Region (1)
China (7) · United States (5) · South Korea (2) · Sweden (2) · Australia (1) · Bosnia and Herzegovina (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Georgia (1) · Greece (1) · Hungary (1) · Malaysia (1) · Moldova (1)
Hyungwoo Cho, Ph.D (1) · John Kuruvilla, FRCPC (1) · Liang Wang, M.D. (1) · Luke Walker, MD (1) · Nirav Shah, MD (1) · Pallawi Torka, MD (1) · Wei Xu (1) · Yihong Yao, PhD (1)
2023 (1)